Drug intelligence / Profile preview

baclofen + diltiazem

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intrathecal

Overview

A combination of baclofen, a GABA-ergic agonist used to manage severe spasticity of cerebral or spinal origin, and diltiazem, a calcium channel blocker used to treat hypertension and manage chronic stable angina. When used together, these medications may cause additive central nervous system depression, impairment of judgment, thinking, and psychomotor skills, and increased risk of hypotension.

Targets

LTCC (Voltage-gated calcium channel (L-type))GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on baclofen + diltiazem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on baclofen + diltiazem.

Explore the full profile